Ixazomib-induced Sweet’s syndrome: A case report
Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet’s syndrome. We present a 62-year-old man who developed drug-induced Sweet’s syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led...
Main Authors: | Jeanne Bellemare, Hannah Laure El Fassy, Alexandra Mereniuk |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X231181034 |
Similar Items
-
Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01) -
Ixazomib Combined With Autologous Stem Cell Transplantation for POEMS Syndrome: A Case Report and Meta-Analysis
by: Ji Ma MD, et al.
Published: (2022-12-01) -
Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib
by: Suheil Albert Atallah-Yunes, et al.
Published: (2018-01-01) -
Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01) -
T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021-09-01)